fr

CARMAT’s Aeson® artificial heart is gradually becoming a reference solution for bridge to transplant in Europe

Share post

CARMAT's Aeson® artificial heart is gradually becoming a reference solution for bridge to transplant in Europe

November 13th 2024

• Milestone of 30 heart transplants post Aeson® support, passed
• Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first ‘Aeson® European User Meeting’ at the end of November

Paris, November 13, 2024 – 7:00 am CET
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe.

Top of page